Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: An opportunity for intervention

Frontiers in Oncology

Volumn 4, Issue DEC, 2014, Pages

  Nouri, Mannan ^a,b   Ratther, Ellca ^c   Stylianou, Nataly ^c   Nelson, Colleen C ^c   Hollier, Brett G ^c   Williams, Elizabeth D ^c,d,e  

^a VANCOUVER PROSTATE CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e MONASH UNIVERSITY   (Australia)

Author keywords

Androgen deprivation therapy; Axl; Brachyury; Castrate resistant; Epithelial to mesenchymal transition; Neuroendocrine; Prostate cancer; Tumor cell plasticity

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL) CHROMONE; AURORA KINASE INHIBITOR; BGB324; BRACHYURY; GI 6301; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR TYROSINE KINASE AXL; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANDROGEN THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CELL PLASTICITY; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; CLINICAL TRIAL (TOPIC); DISEASE COURSE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; NEUROENDOCRINE TRANSDIFFERENTIATION; NEUROSECRETORY CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; VISCERAL METASTASIS;

EID: 84922522895     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00370     Document Type: Review

References (89)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin (2010) 60:277-300. doi: 10.3322/caac.20073
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin (2014) 64:9-29. doi:10.3322/caac.21208
3. Dreicer R, MacLean D, Suri A, Stadler WM, Shevrin D, Hart L, et al. Phase I/II trial of orteronel (TAK-700)-an investigational 17,20-lyase inhibitor-in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res (2014) 20:1335-44. doi:10.1158/1078-0432.CCR-13-2436
4. Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov (2013) 3:1020-9. doi:10.1158/2159-8290.CD-13-0226
5. Rathkopf DE, Morris MJ, Fox JJ, Danila DC, Slovin SF, Hager JH, et al. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol (2013) 31:3525-30. doi:10.1200/JCO.2013.50.1684
6. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol (2014) 65:467-79. doi:10.1016/j.eururo.2013.11.002
7. Fujimoto N, Miyamoto H, Mizokami A, Harada S, Nomura M, Ueta Y, et al. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells. Cancer Invest (2007) 25:32-7. doi:10.1080/07357900601130698
8. Tsao CK, Galsky MD, Small AC, Yee T, Oh WK. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC). BJU Int (2012) 110:1580-8. doi:10.1111/j.1464-410X.2012.11445.x
9. Attar RM, Takimoto CH, Gottardis MM. Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res (2009) 15:3251-5. doi:10.1158/1078-0432.CCR-08-1171
10. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res (2008) 68:5469-77. doi:10.1158/0008-5472.CAN-08-0594
11. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet (1995) 9:401-6. doi:10.1038/ng0495-401
12. Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Janne OA, et al. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res (2009) 69:8141-9. doi:10.1158/0008-5472.CAN-09-0919
13. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res (2008) 68:6407-15. doi:10.1158/0008-5472.CAN-07-5997
14. Lai JJ, Lai KP, Chuang KH, Chang P, Yu IC, Lin WJ, et al. Monocyte/macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-alpha expression. J Clin Invest (2009) 119:3739-51. doi:10.1172/JCI39335
15. Loberg RD, Ying C, Craig M, Yan L, Snyder LA, Pienta KJ. CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia (2007) 9:556-62. doi:10.1593/neo.07307
16. Lubik AA, Gunter JH, Hollier BG, Ettinger S, Fazli L, Stylianou N, et al. IGF2 increases de novo steroidogenesis in prostate cancer cells. Endocr Relat Cancer (2013) 20:173-86. doi:10.1530/ERC-12-0250
17. Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S, et al. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res (2012) 72:527-36. doi:10.1158/0008-5472.CAN-11-3004
18. Zhu P, Baek SH, Bourk EM, Ohgi KA, Garcia-Bassets I, Sanjo H, et al. Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell (2006) 124:615-29. doi:10.1016/j.cell.2005.12.032
19. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res (2009) 11:R46. doi:10.1186/bcr2333
20. Chaffer CL, Thompson EW, Williams ED. Mesenchymal to epithelial transition in development and disease. Cells Tissues Organs (2007) 185:7-19. doi:10.1159/000101298
21. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, et al. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol (2007) 213:374-83. doi:10.1002/jcp.21223
22. Said NABM, Williams ED. Remodelling the malignant phenotype: impact of EMT. Drug Discov Today Dis Models (2009) 6:21-5. doi:10.1016/j.ddmod.2008.12.002
23. Thompson EW, Williams ED. EMT and MET in carcinoma-clinical observations, regulatory pathways and new models. Clin Exp Metastasis (2008) 25:591-2. doi:10.1007/s10585-008-9189-8
24. Bhangu A, Wood G, Mirnezami A, Darzi A, Tekkis P, Goldin R. Epithelial mesenchymal transition in colorectal cancer: seminal role in promoting disease progression and resistance to neoadjuvant therapy. Surg Oncol (2012) 21:316-23. doi:10.1016/j.suronc.2012.08.003
25. Ding W, Nowakowski GS, Knox TR, Boysen JC, Maas ML, Schwager SM, et al. Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. Br J Haematol (2009) 147:471-83. doi:10.1111/j.1365-2141.2009.07868.x
26. Kim SH, Yu MA, Ryu ES, Jang YH, Kang DH. Indoxyl sulfate-induced epithelial-to-mesenchymal transition and apoptosis of renal tubular cells as novel mechanisms of progression of renal disease. Lab Invest (2012) 92:488-98. doi:10.1038/labinvest.2011.194
27. Turley EA, Veiseh M, Radisky DC, Bissell MJ. Mechanisms of disease: epithelial-mesenchymal transition-does cellular plasticity fuel neoplastic progression? Nat Clin Pract Oncol (2008) 5:280-90. doi:10.1038/ncponc1089
28. Das R, Gregory PA, Hollier BG, Tilley WD, Selth LA. Epithelial plasticity in prostate cancer: principles and clinical perspectives. Trends Mol Med (2014) 20(11):643-51. doi:10.1016/j.molmed.2014.09.004
29. Marin-Aguilera M, Codony-Servat J, Reig O, Lozano JJ, Fernandez PL, Pereira MV, et al. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer. Mol Cancer Ther (2014) 13:1270-84. doi:10.1158/1535-7163.MCT-13-0775
30. Ren D, Wang M, Guo W, Huang S, Wang Z, Zhao X, et al. Double-negative feedback loop between ZEB2 and miR-145 regulates epithelial-mesenchymal transition and stem cell properties in prostate cancer cells. Cell Tissue Res (2014) 358(3):763-78. doi:10.1007/s00441-014-2001-y
31. Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera JM, Reuter VE, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol (2014) 38:756-67. doi:10.1097/PAS.0000000000000208
32. Abrahamsson PA, Falkmer S, Falt K, Grimelius L. The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker". Pathol Res Pract (1989) 185:373-80. doi:10.1016/s0344-0338(89)80016-0
33. Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol (2004) 45:586-92. doi:10.1016/j.eururo.2003.11.032
34. Ito T, Yamamoto S, Ohno Y, Namiki K, Aizawa T, Akiyama A, et al. Up-regulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence. Oncol Rep (2001) 8:1221.
35. Jiborn T, Bjartell A, Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology (1998) 51:585-9. doi:10.1016/S0090-4295(97)00684-5
36. di Sant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer (1992) 70:254-68. doi:10.1002/1097-0142(19920701)70:1+<254::AID-CNCR2820701312>3.0.CO;2-E
37. Wafa LA, Palmer J, Fazli L, Hurtado-Coll A, Bell RH, Nelson CC, et al. Comprehensive expression analysis of L-DOPA decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors. Hum Pathol (2007) 38:161-70. doi:10.1016/j.humpath.2006.07.003
38. Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol (2005) 47:147-55. doi:10.1016/j.eururo.2004.09.007
39. Yuan T-C, Veeramani S, Lin F-F, Kondrikou D, Zelivianski S, Igawa T, et al. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr Relat Cancer (2006) 13:151-67. doi:10.1677/erc.1.01043
40. Huang J, Yao JL, di Sant'Agnese PA, Yang Q, Bourne PA, Na Y. Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Prostate (2006) 66:1399-406. doi:10.1002/pros.20434
41. Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, et al. Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res (2014) 20:2846-50. doi:10.1158/1078-0432.ccr-13-3309
42. Hansel DE, Nakayama M, Luo J, Abukhdeir AM, Park BH, Bieberich CJ, et al. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate (2009) 69:603-9. doi:10.1002/pros.20910
43. Lotan TL, Gupta NS, Wang W, Toubaji A, Haffner MC, Chaux A, et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol (2011) 24:820-8. doi:10.1038/modpathol.2011.7
44. Palmgren JS, Karavadia SS, Wakefield MR. Unusual and underappreciated: small cell carcinoma of the prostate. Semin Oncol (2007) 34:22-9. doi:10.1053/j.seminoncol.2006.10.026
45. Williamson SR, Zhang S, Yao JL, Huang J, Lopez-Beltran A, Shen S, et al. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol (2011) 24:1120-7. doi:10.1038/modpathol.2011.56
46. Bonkhoff H, Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate (1996) 28:98-106. doi:10.1002/(SICI)1097-0045(199602)28:2<98:AID-PROS4>3.0.CO;2-J
47. Bonkhoff H, Wernert N, Dhom G, Remberger K. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate (1991) 19:91-8. doi:10.1002/pros.2990190202
48. Lin D, Wyatt AW, Xue H, Wang Y, Dong X, Haegert A, et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res (2014) 74:1272-83. doi:10.1158/0008-5472.CAN-13-2921-T
49. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, et al. LNCaP model of human prostatic carcinoma. Cancer Res (1983) 43:1809-18.
50. Shen R, Dorai T, Szaboles M, Katz AE, Olsson CA, Buttyan R. Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium. Urol Oncol (1997) 3:67-75. doi:10.1016/S1078-1439(97)00039-2
51. Zelivianski S, Verni M, Moore C, Kondrikov D, Taylor R, Lin M-F. Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype. Biochim Biophys Acta (2001) 1539:28-43. doi:10.1016/S0167-4889(01)00087-8
52. Wright ME, Tsai M-J, Aebersold R. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol (2003) 17:1726-37. doi:10.1210/me.2003-0031
53. Burchardt T, Burchardt M, Chen MW, Cao Y, de la Taille A, Shabsigh A, et al. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol (1999) 162:1800-5. doi:10.1016/S0022-5347(05)68241-9
54. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJM, van der Kwast TH, et al. Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model. Am J Pathol (1999) 154:543-51. doi:10.1016/S0002-9440(10)65300-X
55. Huss WJ, Gregory CW, Smith GJ. Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft: association with tumor cell proliferation prior to recurrence. Prostate (2004) 60:91-7. doi:10.1002/pros.20032
56. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, et al. Androgen deprivation of the PC-310 human prostate cancer model system induces neuroendocrine differentiation. Cancer Res (2000) 60:741-8.
57. Izumi K, Fang LY, Mizokami A, Namiki M, Li L, Lin WJ, et al. Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation. EMBO Mol Med (2013) 5:1383-401. doi:10.1002/emmm.201202367
58. Lin TH, Izumi K, Lee SO, Lin WJ, Yeh S, Chang C. Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (enzalutamide) or casodex (bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death Dis (2013) 4:e764. doi:10.1038/cddis.2013.270
59. Lin TH, Lee SO, Niu Y, Xu D, Liang L, Li L, et al. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/enzalutamide versus anti-androgen receptor ASC-J9(R) lead to promotion versus suppression of prostate cancer metastasis. J Biol Chem (2013) 288:19359-69. doi:10.1074/jbc.M113.477216
60. Gannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson AM, Saad F. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods (2009) 348:9-17. doi:10.1016/j.jim.2009.06.004
61. Yamada T. Caudalization by the amphibian organizer: Brachyury, convergent extension and retinoic acid. Development (1994) 120:3051-62.
62. Fernando RI, Litzinger M, Trono P, Hamilton DH, Schlom J, Palena C. The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. J Clin Invest (2010) 120:533-44. doi:10.1172/JCI38379
63. Imajyo I, Sugiura T, Kobayashi Y, Shimoda M, Ishii K, Akimoto N, et al. T-box transcription factor Brachyury expression is correlated with epithelial-mesenchymal transition and lymph node metastasis in oral squamous cell carcinoma. Int J Oncol (2012) 41:1985-95. doi:10.3892/ijo.2012.1673
64. Roselli M, Fernando RI, Guadagni F, Spila A, Alessandroni J, Palmirotta R, et al. Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer. Clin Cancer Res (2012) 18:3868-79. doi:10.1158/1078-0432.CCR-11-3211
65. Shimoda M, Sugiura T, Imajyo I, Ishii K, Chigita S, Seki K, et al. The T-box transcription factor Brachyury regulates epithelial-mesenchymal transition in association with cancer stem-like cells in adenoid cystic carcinoma cells. BMC Cancer (2012) 12:377. doi:10.1186/1471-2407-12-377
66. Thoma C. Prostate cancer: Brachyury-a biomarker for progression and prognosis? Nat Rev Urol (2014) 11:485. doi:10.1038/nrurol.2014.184
67. Perets R, Kaplan T, Stein I, Hidas G, Tayeb S, Avraham E, et al. Genome-wide analysis of androgen receptor targets reveals COUP-TF1 as a novel player in human prostate cancer. PLoS One (2012) 7:e46467. doi:10.1371/journal.pone.0046467
68. Pinto F, Pertega-Gomes N, Pereira MS, Vizcaino JR, Monteiro P, Henrique RM, et al. T-box transcription factor Brachyury is associated with prostate cancer progression and aggressiveness. Clin Cancer Res (2014) 20:4949-61. doi:10.1158/1078-0432.CCR-14-0421
69. Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C. IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res (2011) 71:5296-306. doi:10.1158/0008-5472.CAN-11-0156
70. Hamilton DH, Litzinger MT, Jales A, Huang B, Fernando RI, Hodge JW, et al. Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant Brachyury-yeast vaccine. Oncotarget (2013) 4:1777-90.
71. Heery CR, Singh H, Jennifer L, Marte JL, Madan RA, O'Sullivan Coyne GH, et al. NCI experience using yeast-Brachyury vaccine (GI-6301) in patients with advanced chordoma. J Clin Oncol (2014) 32:abstract 3081.
72. Asiedu MK, Beauchamp-Perez FD, Ingle JN, Behrens MD, Radisky DC, Knutson KL. Axl induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene (2014) 33:1316-24. doi:10.1038/onc.2013.57
73. Paccez JD, Vasques GJ, Correa RG, Vasconcellos JF, Duncan K, Gu X, et al. The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target. Oncogene (2013) 32:689-98. doi:10.1038/onc.2012.89
74. Li Y, Jia L, Ren D, Liu C, Gong Y, Wang N, et al. Axl mediates tumor invasion and chemosensitivity through PI3K/Akt signaling pathway and is transcriptionally regulated by slug in breast carcinoma. IUBMB Life (2014) 66:507-18. doi:10.1002/iub.1285
75. Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res (2010) 70:1544-54. doi:10.1158/0008-5472.CAN-09-2997
76. Ye X, Li Y, Stawicki S, Couto S, Eastham-Anderson J, Kallop D, et al. An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene (2010) 29:5254-64. doi:10.1038/onc.2010.268
77. Zhang YX, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orfi L, et al. AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res (2008) 68:1905-15. doi:10.1158/0008-5472.CAN-07-2661
78. Castellone MD, Carlomagno F, Salvatore G, Santoro M. Receptor tyrosine kinase inhibitors in thyroid cancer. Best Pract Res Clin Endocrinol Metab (2008) 22:1023-38. doi:10.1016/j.beem.2008.09.012
79. Timar J, Dome B. Antiangiogenic drugs and tyrosine kinases. Anticancer Agents Med Chem (2008) 8:462-9. doi:10.2174/187152008784533035
80. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther (2011) 10:2298-308. doi:10.1158/1535-7163.MCT-11-0264
81. Smith MR, Sweeney CJ, Corn PG, Rathkopf DE, Smith DC, Hussain M, et al. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. J Clin Oncol (2014) 32(30):3391-9. doi:10.1200/JCO.2013.54.5954
82. Zhang XQ, Kondrikov D, Yuan TC, Lin FF, Hansen J, Lin MF. Receptor protein tyrosine phosphatase alpha signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells. Oncogene (2003) 22:6704-16. doi:10.1038/sj.onc.1206764
83. Hong SK, Kim JH, Lin MF, Park JI. The Raf/MEK/extracellular signal-regulated kinase 1/2 pathway can mediate growth inhibitory and differentiation signaling via androgen receptor downregulation in prostate cancer cells. Exp Cell Res (2011) 317:2671-82. doi:10.1016/j.yexcr.2011.08.008
84. Hou CH, Lin FL, Hou SM, Liu JF. Cyr61 promotes epithelial-mesenchymal transition and tumor metastasis of osteosarcoma by Raf-1/MEK/ERK/Elk-1/TWIST-1 signaling pathway. Mol Cancer (2014) 13:236. doi:10.1186/1476-4598-13-236
85. Karamitopoulou E, Zlobec I, Gloor B, Kondi-Pafiti A, Lugli A, Perren A. Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC). J Transl Med (2013) 11:311. doi:10.1186/1479-5876-11-311
86. Wan XB, Long ZJ, Yan M, Xu J, Xia LP, Liu L, et al. Inhibition of Aurora-A suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells. Carcinogenesis (2008) 29:1930-7. doi:10.1093/carcin/bgn176
87. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 1:487-95. doi:10.1158/2159-8290.cd-11-0130
88. D'Assoro AB, Liu T, Quatraro C, Amato A, Opyrchal M, Leontovich A, et al. The mitotic kinase Aurora-A promotes distant metastases by inducing epithelial-to-mesenchymal transition in ER alpha(+) breast cancer cells. Oncogene (2014) 33:599-610. doi:10.1038/onc.2012.628
89. McKeithen D, Graham T, Chung LW, Odero-Marah V. Snail transcription factor regulates neuroendocrine differentiation in LNCaP prostate cancer cells. Prostate (2010) 70:982-92. doi:10.1002/pros.21132